TTP
MCID: THR005
MIFTS: 55

Thrombotic Thrombocytopenic Purpura (TTP) malady

Categories: Blood diseases, Genetic diseases, Rare diseases, Nephrological diseases

Aliases & Classifications for Thrombotic Thrombocytopenic Purpura

Aliases & Descriptions for Thrombotic Thrombocytopenic Purpura:

Name: Thrombotic Thrombocytopenic Purpura 12 25 14
Purpura, Thrombotic Thrombocytopenic 25 42 69
Microangiopathic Hemolytic Anemia 25 69
Congenital Thrombotic Thrombocytopenic Purpura 69
Familial Thrombotic Thrombocytopenia Purpura 25
Familial Thrombotic Thrombocytopenic Purpura 69
Thrombotic Microangiopathy, Familial 25
Moschcowitz's Syndrome 12
Moschkowitz Disease 25
Ttp 25

Classifications:



External Ids:

Disease Ontology 12 DOID:10772
ICD10 33 M31.1
MeSH 42 D011697
NCIt 47 C78797
UMLS 69 C0034155

Summaries for Thrombotic Thrombocytopenic Purpura

Genetics Home Reference : 25 Thrombotic thrombocytopenic purpura is a rare disorder that causes blood clots (thrombi) to form in small blood vessels throughout the body. These clots can cause serious medical problems if they block vessels and restrict blood flow to organs such as the brain, kidneys, and heart. Resulting complications can include neurological problems (such as personality changes, headaches, confusion, and slurred speech), fever, abnormal kidney function, abdominal pain, and heart problems.

MalaCards based summary : Thrombotic Thrombocytopenic Purpura, also known as purpura, thrombotic thrombocytopenic, is related to lupus erythematosus and influenza, and has symptoms including fever, tremor and reduced consciousness/confusion. An important gene associated with Thrombotic Thrombocytopenic Purpura is ADAMTS13 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs rituximab and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and brain, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 71 Thrombotic thrombocytopenic purpura (TTP or Moschcowitz syndrome) is a rare disorder of the... more...

Related Diseases for Thrombotic Thrombocytopenic Purpura

Diseases in the Thrombotic Thrombocytopenic Purpura family:

Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Acquired

Diseases related to Thrombotic Thrombocytopenic Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
id Related Disease Score Top Affiliating Genes
1 lupus erythematosus 30.2 F3 PLAT SELP SERPINC1 VWF
2 influenza 29.9 F3 SERPINC1 SERPINF2
3 essential thrombocythemia 29.7 F3 SERPINC1 VWF
4 membranoproliferative glomerulonephritis 29.6 ADAMTS13 F3 SERPINC1 VWF
5 myocardial infarction 29.0 ADAMTS13 F3 PLAT SELP SERPINC1 SERPINF2
6 thrombotic thrombocytopenic purpura, familial 12.7
7 thrombotic thrombocytopenic purpura, acquired 12.6
8 purpura 11.2
9 familial thrombotic thrombocytopenia purpura 11.2
10 hemolytic-uremic syndrome 10.7
11 systemic lupus erythematosus 10.4
12 pancreatitis 10.3
13 retinitis 10.3
14 thrombocytopenia 10.3
15 urogenital adysplasia 10.3 THBD VWF
16 endotheliitis 10.3
17 immune-mediated encephalomyelitis 10.3 THBD VWF
18 connective tissue disease 10.2
19 alpha-2-macroglobulin deficiency 10.2 F3 VWF
20 acute pancreatitis 10.2
21 central congenital hypothyroidism 10.2 ADAMTS13 F3
22 methylmalonic aciduria and homocystinuria, cblc type 10.2 ADAMTS13 CD46
23 hepatitis 10.2
24 mixed connective tissue disease 10.2
25 adult-onset still's disease 10.2
26 disseminated intravascular coagulation 10.2
27 immunodeficiency 32a, mycobacteriosis, autosomal dominant 10.2 PLAT THBD
28 metaphyseal chondrodysplasia with cone-shaped epiphyses, normal hair, and normal hands 10.2 PLAT THBD
29 sialadenitis 10.2 THBD VWF
30 fletcher factor deficiency 10.2 F3 VWF
31 vcl-related dilated cardiomyopathy 10.2 ADAMTS13 SELP VWF
32 severe nonproliferative diabetic retinopathy 10.2 ADAMTS13 SELP VWF
33 subclavian artery aneurysm 10.2 F3 SELP
34 retinal detachment 10.2
35 hemolytic anemia 10.2
36 myotonic dystrophy 10.2 F3 VWF
37 sertoli cell tumor 10.1 F3 SERPINC1
38 freiberg's disease 10.1 F3 SERPINC1
39 pancreatic ductal carcinoma 10.1 F3 SERPINC1
40 chorioretinal scar 10.1 F3 SERPINC1
41 macular degeneration, age-related, 4 10.1 CD46 CFI
42 spinal cord lipoma 10.1 F3 SERPINC1
43 antiphospholipid syndrome 10.1
44 thrombosis 10.1
45 hepatitis c 10.1
46 malignant hypertension 10.1
47 multiple myeloma 10.1
48 bone marrow necrosis 10.1
49 midline cystocele 10.1 F3 SERPINC1
50 basilar artery insufficiency 10.1 SELP THBD VWF

Graphical network of the top 20 diseases related to Thrombotic Thrombocytopenic Purpura:



Diseases related to Thrombotic Thrombocytopenic Purpura

Symptoms & Phenotypes for Thrombotic Thrombocytopenic Purpura

UMLS symptoms related to Thrombotic Thrombocytopenic Purpura:


fever, tremor, reduced consciousness/confusion

MGI Mouse Phenotypes related to Thrombotic Thrombocytopenic Purpura:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 THBD THBS1 VWF CD46 F3 PLAT
2 hematopoietic system MP:0005397 9.97 F3 PLAT SELP SERPINC1 THBD THBS1
3 homeostasis/metabolism MP:0005376 9.96 ADAMTS13 CFI F3 PLAT SELP SERPINC1
4 immune system MP:0005387 9.76 ADAMTS13 F3 PLAT SELP SERPINC1 THBD
5 renal/urinary system MP:0005367 9.35 CFI SELP SERPINC1 THBD THBS1
6 vision/eye MP:0005391 9.17 ADAMTS13 CD46 F3 PLAT SELP SERPINC1

Drugs & Therapeutics for Thrombotic Thrombocytopenic Purpura

Drugs for Thrombotic Thrombocytopenic Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
2
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613 2171
3
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
4
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 53-03-2 5865
9
Caffeic acid Experimental Phase 4,Phase 3 331-39-5 1549111
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13
Dexlansoprazole Phase 4,Phase 2 138530-94-6, 103577-45-3 9578005
14 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
15 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
16 gamma-Globulins Phase 4,Phase 2,Phase 3
17 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
18 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 3
19 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 3
20 Antiemetics Phase 4,Phase 3,Phase 2
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Early Phase 1
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Early Phase 1
23 Autonomic Agents Phase 4,Phase 3,Phase 2
24 glucocorticoids Phase 4,Phase 3,Phase 2,Early Phase 1
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
26 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
28 Methylprednisolone acetate Phase 4,Phase 2,Phase 3
29 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 3
30 Neuroprotective Agents Phase 4,Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
32 Prednisolone acetate Phase 4,Phase 2,Phase 3
33 Prednisolone hemisuccinate Phase 4,Phase 2,Phase 3
34 Prednisolone phosphate Phase 4,Phase 2,Phase 3
35 Protective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
36 BB 1101 Phase 4,Phase 2,Phase 3
37 Dexamethasone 21-phosphate Phase 4,Phase 2,Phase 3
38 Dexamethasone acetate Phase 4,Phase 2,Phase 3 1177-87-3
39 Antioxidants Phase 4,Phase 2,Phase 3,Early Phase 1
40 Antacids Phase 4
41 Anti-Ulcer Agents Phase 4
42 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
43 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
44
Proton pump inhibitors Phase 4,Phase 2,Phase 3
45 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
46
protease inhibitors Phase 4,Phase 3,Phase 2
47
Selenium Approved, Vet_approved Phase 2, Phase 3 7782-49-2
48
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
49
Acetaminophen Approved Phase 3,Phase 2 103-90-2 1983
50
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244

Interventional clinical trials:

(show top 50) (show all 240)
id Name Status NCT ID Phase
1 Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Completed NCT00820469 Phase 4
2 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4
3 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
4 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4
5 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4
6 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
7 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4
8 Immunomodulation With Romiplostim in Young Adults With ITP Recruiting NCT02760251 Phase 4
9 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Recruiting NCT02556814 Phase 4
10 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4
11 Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Withdrawn NCT01754545 Phase 4
12 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4
13 Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP Unknown status NCT01805648 Phase 3
14 Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia Unknown status NCT01763658 Phase 2, Phase 3
15 A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076399 Phase 3
16 Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10 Completed NCT00168038 Phase 3
17 P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00603642 Phase 3
18 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT02076412 Phase 3
19 Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura Completed NCT00699140 Phase 3
20 Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults Completed NCT00426270 Phase 3
21 Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients Completed NCT00362349 Phase 3
22 A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Completed NCT00504075 Phase 3
23 Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura Completed NCT00657410 Phase 3
24 Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00116688 Phase 3
25 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura Completed NCT01071954 Phase 3
26 Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3
27 A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) Completed NCT00770562 Phase 3
28 AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy Completed NCT00102336 Phase 3
29 AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy Completed NCT00102323 Phase 3
30 Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Completed NCT01730352 Phase 2, Phase 3
31 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Completed NCT00540423 Phase 3
32 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Completed NCT00828750 Phase 3
33 IGIV Study for Chronic ITP Patients Ages 3-70 Completed NCT00511147 Phase 3
34 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Completed NCT01520909 Phase 3
35 High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP Completed NCT00451594 Phase 3
36 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP Completed NCT00508820 Phase 3
37 Open Label Extension Study of AMG 531 in Japanese Subjects With ITP Completed NCT00440037 Phase 2, Phase 3
38 EXTEND (Eltrombopag Extended Dosing Study) Completed NCT00351468 Phase 3
39 A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. Completed NCT00376077 Phase 3
40 rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Completed NCT01525836 Phase 3
41 Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) Completed NCT01506414 Phase 3
42 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients Completed NCT01444417 Phase 3
43 RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag Completed NCT00370331 Phase 3
44 Efficacy and Safety of IVIG-L in ITP Patients Completed NCT00151840 Phase 3
45 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) Completed NCT01438840 Phase 3
46 Study of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP Completed NCT00774202 Phase 2, Phase 3
47 Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Completed NCT00749112 Phase 2, Phase 3
48 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP Completed NCT01734044 Phase 3
49 Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
50 Rituximab as Second Line Treatment for ITP Completed NCT00344149 Phase 3

Search NIH Clinical Center for Thrombotic Thrombocytopenic Purpura

Cochrane evidence based reviews: purpura, thrombotic thrombocytopenic

Genetic Tests for Thrombotic Thrombocytopenic Purpura

Anatomical Context for Thrombotic Thrombocytopenic Purpura

MalaCards organs/tissues related to Thrombotic Thrombocytopenic Purpura:

39
Kidney, Heart, Brain, Endothelial, Liver, B Cells, Bone Marrow

Publications for Thrombotic Thrombocytopenic Purpura

Articles related to Thrombotic Thrombocytopenic Purpura:

(show top 50) (show all 855)
id Title Authors Year
1
The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura. ( 27866840 )
2017
2
Dynamic changes in absolute immature platelet count suggest the presence of a coexisting immune process in the setting of thrombotic thrombocytopenic purpura. ( 28083876 )
2017
3
A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura. ( 27885868 )
2017
4
Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. ( 27079482 )
2016
5
High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. ( 26566785 )
2016
6
Isolated thrombocytopenia and liver function abnormalities characterizing an atypical presentation of thrombotic thrombocytopenic purpura. ( 27542956 )
2016
7
Successful rituximab treatment in an elderly patient with recurrent thrombotic thrombocytopenic purpura. ( 27498731 )
2016
8
CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides. ( 26747250 )
2016
9
Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. ( 27009919 )
2016
10
Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. ( 27221364 )
2016
11
Differentiation of pernicious anemia from thrombotic thrombocytopenic purpura: The clinical value of subtle pathologic findings. ( 27765664 )
2016
12
Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy. ( 27648610 )
2016
13
Acute myocardial infarction as the initial thrombotic event of thrombotic thrombocytopenic purpura. ( 26757016 )
2016
14
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. ( 26863353 )
2016
15
Systemic Lupus Erythematosus Presenting as Refractory Thrombotic Thrombocytopenic Purpura: A Diagnostic and Management Challenge. A Case Report and Concise Review of the Literature. ( 27777394 )
2016
16
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. ( 27132698 )
2016
17
Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura. ( 27501520 )
2016
18
Familial acquired thrombotic thrombocytopenic purpura in siblings - no immunogenetic link with associated human leucocyte antigens. ( 27859681 )
2016
19
Congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) caused by novel ADAMTS13 mutations. ( 26085195 )
2016
20
N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. ( 28011677 )
2016
21
Use of the automated fragmented red cell count for monitoring patients with thrombotic thrombocytopenic purpura. ( 27565612 )
2016
22
Carboxiterminal pro-endothelin-1 as an endothelial cell biomarker in thrombotic thrombocytopenic purpura. ( 26763086 )
2016
23
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro. ( 27040144 )
2016
24
Eculizumab refractory thrombotic thrombocytopenic purpura secondary to post-endoscopic retrograde cholangiopancreatography pancreatitis in a patient. ( 27987277 )
2016
25
Thrombotic thrombocytopenic purpura presenting as acute coronary syndrome. ( 27525072 )
2016
26
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. ( 27060171 )
2016
27
Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura. Blood. 1947;2(6):542-554. ( 26769767 )
2016
28
Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13. ( 26867546 )
2016
29
Idiopathic thrombotic thrombocytopenic purpura: strongest risk factor for relapse from remission is having had a relapse. ( 27514869 )
2016
30
The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical and in silico study. ( 26272487 )
2016
31
Acute pancreatitis-induced thrombotic thrombocytopenic purpura with recurrent acute pancreatitis. ( 26905311 )
2016
32
Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. ( 27590601 )
2016
33
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. ( 27868334 )
2016
34
Rainbow of hemolysis associated with acquired thrombotic thrombocytopenic purpura. ( 27530891 )
2016
35
Inherited Thrombotic Thrombocytopenic Purpura (Upshaw Schulman Syndrome) as Differential Diagnosis to Neonatal Septicaemia with Disseminated Intravascular Coagulation - a Case Series. ( 27383044 )
2016
36
ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. ( 27040023 )
2016
37
Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter non-comparative study. ( 27643485 )
2016
38
Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test. ( 27435143 )
2016
39
Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. ( 26779871 )
2016
40
ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. ( 27887777 )
2016
41
Pregnancy shortly after an acute episode of severe acquired thrombotic thrombocytopenic purpura. ( 27543396 )
2016
42
More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. ( 26907228 )
2016
43
A Thought on Possible Pathogenesis of Ebola Viral Hemorrhagic Disease and Potential Treatments: Could it Be Thrombotic Thrombocytopenic Purpura-Like Syndrome? ( 26626044 )
2016
44
Coombs Positive Thrombotic Thrombocytopenic Purpura in a Male Pediatric Patient: An Urgent Diagnostic Challenge. ( 27195703 )
2016
45
Acute thrombotic thrombocytopenic purpura after sleeve gastrectomy: a case report and review of the literature. ( 27989525 )
2016
46
Thrombotic thrombocytopenic purpura: The role of ADAMTS13. ( 27505881 )
2016
47
When the picture is fragmented: Vitamin B12 deficiency masquerading as thrombotic thrombocytopenic purpura. ( 27308258 )
2016
48
Diagnosis and management of acquired thrombotic thrombocytopenic purpura in southeast China: a single center experience of 60 cases. ( 27878664 )
2016
49
A case of refractory thrombotic thrombocytopenic purpura treated with plasmapheresis and rituximab. ( 27384362 )
2016
50
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura. ( 27662014 )
2016

Variations for Thrombotic Thrombocytopenic Purpura

Expression for Thrombotic Thrombocytopenic Purpura

Search GEO for disease gene expression data for Thrombotic Thrombocytopenic Purpura.

Pathways for Thrombotic Thrombocytopenic Purpura

GO Terms for Thrombotic Thrombocytopenic Purpura

Cellular components related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.92 CD46 CFI F3 PLAT SERPINC1 SERPINF2
2 extracellular region GO:0005576 9.76 ADAMTS13 CFI F3 PLAT SERPINC1 SERPINF2
3 extracellular matrix GO:0031012 9.71 F3 PLAT THBS1 VWF
4 cell surface GO:0009986 9.5 ADAMTS13 CD46 F3 PLAT SERPINF2 THBD
5 platelet alpha granule GO:0031091 9.43 THBS1 VWF
6 platelet alpha granule lumen GO:0031093 9.43 SERPINF2 THBS1 VWF
7 fibrinogen complex GO:0005577 9.37 SERPINF2 THBS1
8 extracellular space GO:0005615 9.28 ADAMTS13 CFI F3 PLAT SELP SERPINC1

Biological processes related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.62 SELP SERPINF2 THBS1 VWF
2 fibrinolysis GO:0042730 9.43 PLAT SERPINF2
3 negative regulation of fibrinolysis GO:0051918 9.43 SERPINF2 THBD THBS1
4 blood coagulation GO:0007596 9.43 ADAMTS13 F3 PLAT SERPINC1 THBD VWF
5 protein O-linked fucosylation GO:0036066 9.4 ADAMTS13 THBS1
6 negative regulation of plasminogen activation GO:0010757 9.37 SERPINF2 THBS1
7 positive regulation of transforming growth factor beta production GO:0071636 9.33 CD46 SERPINF2 THBS1
8 hemostasis GO:0007599 9.02 ADAMTS13 F3 SERPINC1 THBD VWF

Molecular functions related to Thrombotic Thrombocytopenic Purpura according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.5 SELP SERPINC1 THBS1
2 integrin binding GO:0005178 9.33 ADAMTS13 THBS1 VWF
3 protease binding GO:0002020 9.26 F3 SERPINC1 SERPINF2 VWF
4 glycoprotein binding GO:0001948 8.92 PLAT SELP THBS1 VWF
5 protein binding GO:0005515 10 ADAMTS13 CD46 CFI F3 PLAT SELP

Sources for Thrombotic Thrombocytopenic Purpura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....